Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB Other Stockholders Equity

Equity items not reported separately, such as additional paid-in capital or treasury stock.

Biogen Inc.NASDAQ: BIIB

Other Stockholders Equity · Q2 FY2026 · quarter ended Jun 2026

Other stockholders equity remains negative

Q2 FY2026 other stockholders equity was $0, compared with $0 a year earlier.

Context

  • Other stockholders equity amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Other stockholders equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Other Stockholders Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Stockholders Equity history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Other Stockholders Equity vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's Jun 2026 other stockholders equity of $0 is the 2nd highest of the 11 companies compared; the peer median is $0.
  • Other stockholders equity amounts to 0.0% of total assets for BIIB, versus a peer median of 0.0%.
BIIB Competitors Peer median
Other Stockholders Equity for BIIB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VRTXVertex Pharmaceuticals IncorporatedSep 2026$32.48B ——99.2%
BIIBBiogen Inc.Jun 2026$0 ——0.0%
AZNAstraZeneca PLCSep 2026$0 —+2.2%0.0%
AMGNAmgen Inc.Jun 2026$0 ——0.0%
PFEPfizer Inc.Jun 2026$0 ——0.0%
REGNRegeneron Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
UTHRUnited Therapeutics CorporationJun 2026$0 ——0.0%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
PTCTPTC Therapeutics, Inc.Jun 2026$0 ——0.0%
IONSIonis Pharmaceuticals, Inc.Sep 2026$0 ——0.0%
LLYEli Lilly and CompanyJun 2026-$2.96B +1.8%—2.1%
Peer median (excluding BIIB) $0+1.8%+2.2%0.0%

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.26B3.42B1.05B2.38B3.01B
Short-term Investments1.54B1.47B00807.2M
Net Receivables1.96B2.14B2.1B1.87B1.87B
Inventory1.35B1.34B2.53B2.46B2.17B
Other Current Assets740.8M1.42B1.18B752.5M1.12B
Total Current Assets7.86B9.79B6.86B7.46B8.97B
Property, Plant & Equipment (Net)3.79B3.7B3.73B3.54B3.32B
Goodwill5.76B5.75B6.22B6.48B6.49B
Intangible Assets2.22B1.85B8.36B9.69B9.18B
Long-term Investments892M705.7M460.7M226.7M750.6M
Tax Assets1.42B1.23B928.6M324.2M292.5M
Other Non-current Assets1.94B1.53B284.3M333.8M431.9M
Total Non-current Assets16.02B14.76B19.99B20.59B20.47B
Total Assets23.88B24.55B26.84B28.05B29.44B
Account Payables589.2M491.5M403.3M424.2M432M
Short-term Debt999.1M0150M1.75B80.4M
Tax Payables174.7M259.9M257.4M548.3M114.8M
Deferred Revenue00000
Other Current Liabilities345.1M1.14B335.1M375.8M2.72B
Total Current Liabilities4.3B3.27B3.43B5.53B3.35B
Long-term Debt6.27B6.28B6.79B4.55B6.58B
Deferred Tax Liabilities694.5M334.7M641.8M190.5M507.6M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.32B944.2M781.1M732.3M458.1M
Total Non-current Liabilities8.62B7.89B8.61B5.8B7.83B
Total Liabilities12.92B11.17B12.05B11.33B11.18B
Common Stock100K100K100K100K100K
Retained Earnings13.91B16.47B17.63B19.26B20.55B
Accumulated OCI(106.7M)(164.9M)(153.7M)(136.2M)(182M)
Other Stockholders Equity00000
Minority Interest63.5M(9.5M)000
Total Equity10.96B13.39B14.8B16.72B18.26B
Total Debt7.6B6.61B7.34B6.63B6.95B
Net Debt5.34B3.19B6.29B4.26B3.94B

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.